Company / Cash & Equivalents
PROTHENA CORP PUBLIC LTD CO Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$307.5M
FY2025
5-year range
$295.4M / $710.4M
FY2021-FY2025
Trend
-50.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 10 years, ranging from $295M in FY2021 to $710M in FY2023.
Based on SEC 10-K filings.
$308M in FY2025 with a 5-year CAGR of -3.9%.
Declined from $710M to $308M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -19.0%
- 5-Year CAGR
- -3.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -3.9%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 50.3% year-over-year.
- Peak cash & equivalents was recorded in FY2023.
- Lowest cash & equivalents in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $307.5M | -50.3% |
| FY2024 | $618.8M | -12.9% |
| FY2023 | $710.4M | +22.7% |
| FY2022 | $579.1M | +96.1% |
| FY2021 | $295.4M | -21.4% |
| FY2020 | $375.7M | -12.1% |
| FY2019 | $427.7M | +2.4% |
| FY2018 | $417.6M | +7.9% |
| FY2017 | $386.9M | +0.0% |
| FY2016 | $386.9M | +31.8% |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 28, 2026